AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8129407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 2490930 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin application (experimental side)
Number of subjects: 21
Study 2490930 — intervention group
Group type: COMPARATOR
Intervention: Control sides (no glycyrrhizin application)
Number of subjects: 21
Study 31069904 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Interdisciplinary Bedside Rounding (SIBR)
Number of subjects: 78
Study 31069904 — intervention group
Group type: COMPARATOR
Intervention: Traditional rounds (Control)
Number of subjects: 78
Study 30915564 — intervention group
Group type: EXPERIMENTAL
Intervention: DTA model based on CT findings alone
Number of subjects: 290
Study 30915564 — intervention group
Group type: EXPERIMENTAL
Intervention: DTA model based on imaging and clinical findings
Number of subjects: 290
Study 28646934 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute delay of peri-prostatic lidocaine injection
Number of subjects: 80
Study 28646934 — intervention group
Group type: COMPARATOR
Intervention: 10-minute delay of peri-prostatic lidocaine injection
Number of subjects: 80
Study 28646934 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset analysis of biopsies 1-3, 4-6, 7-9 and 10-12 with 2-minute delay
Number of subjects: 80
Study 26051236 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 75
Study 23816438 — intervention group
Group type: EXPERIMENTAL
Intervention: High vegetable content meal
Number of subjects: 276
Study 23816438 — intervention group
Group type: EXPERIMENTAL
Intervention: High-meat meal
Number of subjects: 276
Study 23816438 — intervention group
Group type: COMPARATOR
Intervention: Control meal (150 g cooked rice, sautéed beef menu containing 40 g raw beef, and 240 g vegetable)
Number of subjects: 276
Study 23816438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-ED meals
Number of subjects: 276
Study 23816438 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased rice content
Number of subjects: 276
Study 20663999 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus famotidine 20 mg twice daily
Number of subjects: 15
Study 20663999 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus lansoprazole 15 mg once daily
Number of subjects: 15
Study 20663999 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg
Number of subjects: 15
Study 19858398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU)
Number of subjects: 1036
Study 19858398 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan/FU (IrFU)
Number of subjects: 1036
Study 19858398 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin/FU (OxFU)
Number of subjects: 1036
Study 19858398 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan alone
Number of subjects: 1036
Study 19858398 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT1A1*28
Number of subjects: 1036
Study 16431254 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of topical 1% testosterone gel (Testim) applied daily for 6 months
Number of subjects: 40
Study 16431254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15203583 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 15203583 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 15203583 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene and Atorvastatin (combined treatment)
Number of subjects: 0
Study 11531673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lockit epidural catheter clamp
Number of subjects: 102
Study 11531673 — intervention group
Group type: COMPARATOR
Intervention: Standard epidural dressing
Number of subjects: 102
Study 9415763 — intervention group
Group type: EXPERIMENTAL
Intervention: Copalite (Harry J. Bosworth Co.) with or without Vitrebond (3M)
Number of subjects: 0
Study 9415763 — intervention group
Group type: COMPARATOR
Intervention: Amalgambond Plus (Parkell)
Number of subjects: 0
Study 8507446 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion
Number of subjects: 28
Study 8507446 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion alone
Number of subjects: 28
Study 3690524 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (MPA) 300 mg X 3 daily for 4 weeks and 500 mg X 2 weekly thereafter
Number of subjects: 123
Study 3690524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (im) medroxyprogesterone acetate (MPA) 500 mg daily for 4 weeks and 500 mg X 2 weekly thereafter
Number of subjects: 123
Study 3690524 — intervention group
Group type: COMPARATOR
Intervention: Both oral and im MPA
Number of subjects: 123
Study 29246264 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP index threshold ≥ 0.5
Number of subjects: 264
Study 26954408 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 32 mg/d and Bupropion 360 mg/d
Number of subjects: 8910
Study 26954408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8910
Study 24232442 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa
Number of subjects: 90
Study 24232442 — intervention group
Group type: EXPERIMENTAL
Intervention: citalopram
Number of subjects: 90
Study 24232442 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 22949154 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg per day
Number of subjects: 502
Study 22949154 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg per day
Number of subjects: 502
Study 20738171 — intervention group
Group type: COMPARATOR
Intervention: 37% phosphoric acid
Number of subjects: 60
Study 20738171 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid + 2% CHX
Number of subjects: 60
Study 20738171 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid + KTP laser
Number of subjects: 60
Study 20738171 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (CPB)
Number of subjects: 60
Study 18422674 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic diastolic dysfunction grade
Number of subjects: 52
Study 18422674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler velocities Em
Number of subjects: 52
Study 18422674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler velocities Am
Number of subjects: 52
Study 18422674 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow propagation velocity
Number of subjects: 52
Study 15731976 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized basic psychological support
Number of subjects: 152
Study 15731976 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional psychological support or intensive assistance
Number of subjects: 152
Study 14572180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-dependent individuals with PTSD
Number of subjects: 558
Study 14572180 — intervention group
Group type: COMPARATOR
Intervention: Cocaine-dependent individuals without PTSD
Number of subjects: 558
Study 14572180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-dependent individuals
Number of subjects: 558
Study 11193558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro64‐0796 75 mg once daily for six weeks
Number of subjects: 308
Study 11193558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 8880944 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental cigarettes with varying nicotine/tar yields (0.08/8.5, 0.17/9.1, 0.37/9.8, 0.48/9.8, 0.74/10.4)
Number of subjects: 32
Study 8880944 — intervention group
Group type: COMPARATOR
Intervention: Commercial 'light' (CL) cigarette (0.71/8.6)
Number of subjects: 32
Study 1892482 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) and newly diagnosed NIDDM
Number of subjects: 1431
Study 1892482 — intervention group
Group type: COMPARATOR
Intervention: Previously diagnosed NIDDM
Number of subjects: 1431
Study 6303794 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 88
Study 6303794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 88
Study 6303794 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole or Ketoconazole
Number of subjects: 88
Study 31804965 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-night salivary cortisol (LNSC)
Number of subjects: 137
Study 31804965 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean urinary free cortisol (mUFC)
Number of subjects: 137
Study 31804965 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mLNSC and mUFC controlled
Number of subjects: 137
Study 30315333 — intervention group
Group type: EXPERIMENTAL
Intervention: Filmed social contact
Number of subjects: 259
Study 30315333 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-study
Number of subjects: 259
Study 30315333 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 259
Study 26171969 — intervention group
Group type: EXPERIMENTAL
Intervention: Realignment therapy using a valgus unloader knee brace plus bilateral neutral foot orthoses and motion control shoes for 12 weeks
Number of subjects: 48
Study 25504030 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary carbohydrate (CHO) group
Number of subjects: 730
Study 25504030 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-regain phase
Number of subjects: 730
Study 23108692 — intervention group
Group type: EXPERIMENTAL
Intervention: Latrepirdine (20 mg) administered orally 3 times daily for 26 weeks
Number of subjects: 403
Study 23108692 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally 3 times daily for 26 weeks
Number of subjects: 403
Study 23108692 — intervention group
Group type: EXPERIMENTAL
Intervention: Latrepirdine
Number of subjects: 403
Study 23108692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 22142350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan/Naproxen Sodium
Number of subjects: 407
Study 22142350 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan
Number of subjects: 407
Study 22142350 — intervention group
Group type: COMPARATOR
Intervention: Naproxen Sodium
Number of subjects: 407
Study 19410462 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy with tamoxifen or anastrozole
Number of subjects: 43
Study 17704975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (240 mg/day)
Number of subjects: 400
Study 17704975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 15761167 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-refilling bowl
Number of subjects: 54
Study 15761167 — intervention group
Group type: COMPARATOR
Intervention: Normal bowl
Number of subjects: 54
Study 11884295 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 2.5 mg/d, riboflavin 5 mg/d, B12 0.4 mg/d
Number of subjects: 131
Study 11884295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 50 mg/d (with folic acid treatment)
Number of subjects: 131
Study 11884295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 10453925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity general conditioning programme (12 weeks, exercise intensity < 60% heart rate reserve, 60 min, 3 times a week)
Number of subjects: 20
Study 10453925 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 20
Study 10453925 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups underwent anthropometric measures and maximal cycling test for VO2max
Number of subjects: 20
Study 7770930 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha‐2b (IFNa) 3 million units three times weekly for 6 months (group A)
Number of subjects: 14
Study 7770930 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 14
Study 2236444 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent reward conditions (easy, difficult, very difficult)
Number of subjects: 0
Study 2236444 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent reward condition
Number of subjects: 0
Study 2236444 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult condition
Number of subjects: 0
Study 348225 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol by pressure-packed aerosol 200 microgram
Number of subjects: 60
Study 348225 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol by intermittent positive pressure ventilation (IPPV) 5 mg
Number of subjects: 60
Study 348225 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol by intermittent positive pressure ventilation (IPPV) 10 mg
Number of subjects: 60
Study 31606289 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric measurements using 3D MRI imaging software
Number of subjects: 24
Study 31606289 — intervention group
Group type: COMPARATOR
Intervention: Kerboul et al method
Number of subjects: 24
Study 31606289 — intervention group
Group type: COMPARATOR
Intervention: Koo and Kim method
Number of subjects: 24
Study 31606289 — intervention group
Group type: COMPARATOR
Intervention: Cherian et al method
Number of subjects: 24
Study 31366975 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide infusion (6.25 mg/kg)
Number of subjects: 20
Study 31366975 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 28264739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day
Number of subjects: 209
Study 28264739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 25589224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT 70 Gy
Number of subjects: 553
Study 25589224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT 74 Gy
Number of subjects: 553
Study 25589224 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT 78 Gy
Number of subjects: 553
Study 25589224 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT/SIB 82 Gy
Number of subjects: 553
Study 25589224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT
Number of subjects: 553
Study 25589224 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 553
Study 23996515 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematurely born children (Cluster A)
Number of subjects: 46
Study 23996515 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematurely born children (overall group)
Number of subjects: 46
Study 23996515 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematurely born children (Cluster B)
Number of subjects: 46
Study 22129109 — intervention group
Group type: EXPERIMENTAL
Intervention: LPC vaccination alone
Number of subjects: 18
Study 22129109 — intervention group
Group type: COMPARATOR
Intervention: PCV2 inoculation/LPC vaccination
Number of subjects: 18
Study 18620831 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin testing with non-ionic monomer RCM
Number of subjects: 32
Study 18620831 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled challenge tests with alternative non-ionic monomer RCM
Number of subjects: 32
Study 17385591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrosorb comfort hydrogel dressing
Number of subjects: 81
Study 15469615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated machines (D) for HCV infected individuals
Number of subjects: 593
Study 15469615 — intervention group
Group type: COMPARATOR
Intervention: Non-dedicated HD machines (ND)
Number of subjects: 593
Study 11509263 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS
Number of subjects: 41
Study 11509263 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 41
Study 9658386 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose sodium valproate for 3 months
Number of subjects: 27
Study 7805431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 251
Study 7805431 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid (500 mg three times daily)
Number of subjects: 251
Study 7805431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 251
Study 7805431 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid
Number of subjects: 251
Study 2780100 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ceftriaxone (group I)
Number of subjects: 50
Study 2780100 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone (group II)
Number of subjects: 50
Study 2780100 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ceftriaxone in peritonitis (group III)
Number of subjects: 50
Study 2780100 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone in peritonitis (group IV)
Number of subjects: 50
Study 2780100 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ceftriaxone
Number of subjects: 50
Study 2780100 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone
Number of subjects: 50
Study 53081 — intervention group
Group type: EXPERIMENTAL
Intervention: 67Gallium-citrate
Number of subjects: 28
Study 53081 — intervention group
Group type: COMPARATOR
Intervention: 111Indium-bleomycin
Number of subjects: 28
Study 31196599 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 31196599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28619649 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated pest management
Number of subjects: 300
Study 28619649 — intervention group
Group type: EXPERIMENTAL
Intervention: Air purifiers
Number of subjects: 300
Study 28619649 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 300
Study 28619649 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study 24890861 — intervention group
Group type: EXPERIMENTAL
Intervention: Early placement (Ea)
Number of subjects: 63
Study 24890861 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed placement (De)
Number of subjects: 63
Study 24890861 — intervention group
Group type: EXPERIMENTAL
Intervention: Late placement (La)
Number of subjects: 63
Study 24890861 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with dehiscence defect
Number of subjects: 63
Study 24890861 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with intrabony defect
Number of subjects: 63
Study 24890861 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants without defect
Number of subjects: 63
Study 24890861 — intervention group
Group type: COMPARATOR
Intervention: Comparison of bBL between implants with and without defect
Number of subjects: 63
Study 24890861 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of BIC among groups
Number of subjects: 63
Study 22359240 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial interventions covering part of women's costs for prenatal and postnatal care
Number of subjects: 3673
Study 22359240 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of midwives in clinical skills
Number of subjects: 3673
Study 22359240 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education training for midwives and village doctors
Number of subjects: 3673
Study 21816309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with a defibrillator (CRT-D)
Number of subjects: 1820
Study 21816309 — intervention group
Group type: COMPARATOR
Intervention: Defibrillator-only
Number of subjects: 1820
Study 19781431 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐N(G)‐monomethyl‐arginine
Number of subjects: 396
Study 19781431 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine dose
Number of subjects: 396
Study 19781431 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in systolic blood pressure at 2 hours
Number of subjects: 396
Study 16719651 — intervention group
Group type: EXPERIMENTAL
Intervention: SSL theory (strategy selection learning)
Number of subjects: 0
Study 16719651 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-performing strategy from participants' repertoires
Number of subjects: 0
Study 16719651 — intervention group
Group type: EXPERIMENTAL
Intervention: SSL model
Number of subjects: 0
Study 12969156 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (250 mmol/day)
Number of subjects: 27
Study 12969156 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (40 mmol/day)
Number of subjects: 27
Study 12969156 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium loading (after high salt intake)
Number of subjects: 27
Study 10713296 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 0
Study 10713296 — intervention group
Group type: COMPARATOR
Intervention: Saccharin (23.7 mg)
Number of subjects: 0
Study 9377617 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/d for 7 days followed by 0.8 mg/d for 7 days)
Number of subjects: 36
Study 9377617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1384146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 0
Study 1384146 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 0
Study 3965001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (T)
Number of subjects: 193
Study 3965001 — intervention group
Group type: COMPARATOR
Intervention: Tetanus-diphtheria toxoid (Td)
Number of subjects: 193
Study 31402223 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL 0.5% plain bupivacaine (100 mg) plus 20 mL liposomal bupivacaine (266 mg)
Number of subjects: 74
Study 31402223 — intervention group
Group type: COMPARATOR
Intervention: 40 mL 0.25% plain bupivacaine (100 mg)
Number of subjects: 74
Study 30515484 — intervention group
Group type: EXPERIMENTAL
Intervention: BB group (anorganic bovine bone and porcine collagen membranes)
Number of subjects: 50
Study 30515484 — intervention group
Group type: COMPARATOR
Intervention: CJ group (synthetic resorbable bone graft substitute made of pure β‐tricalcium phosphate and porcine pericardium collagen membranes)
Number of subjects: 50
Study 30515484 — intervention group
Group type: EXPERIMENTAL
Intervention: BB group
Number of subjects: 50
Study 30515484 — intervention group
Group type: COMPARATOR
Intervention: CJ group
Number of subjects: 50
Study 26655594 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium monotherapy
Number of subjects: 61
Study 26655594 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine monotherapy
Number of subjects: 61